PIK3CA and neoplasm: Together with alpelisib, the FDA also approved the companion diagnostic therascreen® PIK3CA test (QIAGEN Manchester, Ltd.)used in SOLAR-1 to select patients who had PIK3CA mutations in tumor tissue specimens and/or in circulating tumor DNA (ctDNA) isolated from plasma specimens [11].